Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD, is joined by Peter Kaiser, MD, to discuss higher molar dose and its translation into clinical practice. They also discussed the challenges they face in treating patients with higher molar doses, including insurance limitations, safety concerns and convincing insurance carriers to switch to a new dose. They shared clinical pearls for helping patients transition to a higher dose.

See the key takeaways below, and listen to the full podcast for all the clinical pearls.

Increasing aflibercept dose for longer drug duration in eyes.

• A deep dive into how increasing aflibercept dose improves drug durability in the eye
• Modeling suggests slower ocular clearance with higher dose of aflibercept

Drug half-life and dosing for anti-VEGF treatments in ophthalmology.

• How the half-life of aflibercept is determined in the eye using PK sampling and modeling
• Highlights of studies include dose regimen modifications and durability of drug in second year

Accelerating aflibercept dosing intervals for wet AMD patients.

• Designing clinical studies translating the "treat and extend" approach to the real world
• Potential benefits of longer-acting eye medication, including increased efficiency and reduced burden on healthcare providers
• Potential biomarkers that indicate a need for frequent VEGF injections in wet AMD patients
• Emphasising the importance of early treatment with the strongest medication for type three lesions to prevent permanent vision loss